Presented at: AACR Annual Meeting On: Apr 10, 2021 Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor By: S. Peng, C. Si, Y. Zhang, R. Van Horn, X. Lin, et. al.
Presented at: AACR Annual Meeting On: Apr 10, 2021 Preclinical characterization of potent and selective next-generation RET inhibitors By: G. Kolakowski, E. Anderson, J. Ballard, B. Brandhuber, K. Condroski, et. al.
Presented at: AACR Annual Meeting On: Apr 10, 2021 Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor By: B. Brandhuber, K. Ku, M. Lallena, C. Baquero, R. Choy, et. al.
Presented at: AACR Annual Meeting On: Apr 10, 2021 Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD) By: S. Bhagwat, B. Zhao, W. Shen, C. Mur2, R. Barr, et. al.
Published in: The Lancet On: Mar 6, 2021 Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study By: Anthony R Mato, MD Nirav N Shah, MD Wojciech Jurczak, MD Chan Y Cheah, MBBS John M Pagel, MD Jennifer A Woyach, MD et al.
Presented at: ASH Annual Meeting On: Dec 7, 2020 LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor In Previously Treated CLL/SLL: Results From The Phase 1/2 BRUIN Study By: A. Mato, J. Pagel, C. Coombs, N. Shah, N. Lamanna, et. al.
Presented at: ASH Annual Meeting On: Dec 5, 2020 LOXO-305, a Next Generation, Highly Selective, NonCovalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study By: M. Wang, N. Shah, A. Alencar, J. Gerson, M. Patel, et. al.
Presented at: ASH Annual Meeting On: Dec 5, 2020 In Vivo Pre-Clinical Evaluation of LOXO-305 Alone and in Combination with Venetoclax, R-CHOP or Obinutuzumab on Human Xenograft Lymphoma Tumor Models in Mice By: E. Gomez, W. Wu, J. Stephens, M. Rosendahl, B. Brandhuber
Presented at: ASH Annual Meeting On: Dec 9, 2019 LOXO-305, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations By: E. Gomez, I. Lippincott, M. Rosendahl, S. Rothenberg, S. Andrews, B. Brandhuber
Presented at: ASH Annual Meeting On: Dec 8, 2019 Results from the First-in-Human, Proof-of-Concept Phase 1 BRUIN Trial in Pretreated B-Cell Malignancies for LOXO-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor By: A. Mato, I. Flinn, J. Pagel, J. Brown, C. Cheah, et. al.
Presented at: Society of Hematologic Oncology Annual Meeting On: Sep 12, 2018 LOXO-305, A Next Generation Non-Covalent BTK Inhibitor, for Overcoming Acquired Resistance to Covalent BTK Inhibitors By: B. Brandhuber, E. Gomez, S. Smith, T. Eary, S. Spencer, et. al.